Becker muscular dystrophy (BMD) is a type of muscular dystrophy, a genetic condition that weakens and damages muscles. It can worsen with age. However, its symptoms are less severe than those of ...

A new article argues dystrophin immunogenicity is an under-examined issue in the treatment of Duchenne muscular dystrophy.

On the basis of these findings and clinical experience, individuals with Becker muscular dystrophy (BMD) are advised to avoid excess physical exertion. Sveen et al. have performed the first study ...

Discover growth opportunities with Edgewise Therapeutics, Inc. in the hypertrophic cardiomyopathy market. Click for my EWTX stock update.

Multiparametric qMRI effectively differentiates between DMD and BMD in ambulatory children ... help differentiate between Duchenne muscular dystrophy and Becker muscular dystrophy early and ...

Researchers from Edgewise Therapeutics Inc. have previously developed and characterized a novel bmx mouse model of Becker muscular dystrophy (BMD), which harbors a deletion of murine Dystrophin exons ...

Lastly, Edgewise Therapeutics reported favorable Phase 2 data from its Becker Muscular Dystrophy (BMD) trial, a development that led Truist Securities to reiterate its Buy rating and steady price ...

The skeletal phenotype in Becker muscular dystrophy: The under-studied cousin of Duchenne Title: P19: Myosin inhibitor EDG-4131 improves pathophysiology and molecular pathology in BMD model mice ...

DMD was first described by French neurologist Guillaume Benjamin Amand Duchenne in the 1860s. However, until the 1980s, ...